Live
- 26/11 prosecutor to Mumbai North Central candidate - Ujjwal Nikam all set for 'new innings' with BJP
- CBI traces shop that sold bullets & cartridges seized from Sandeshkhali
- IPL 2024: Rasikh and Mukesh pick three-fers as Delhi Capitals beat Mumbai Indians by 10 runs
- 27 Indian startups secure over $222 million in funding this week
- Final Olympic qualifiers: India's Maheshwari leads the field heading into final day
- Govt allows export of 99,150 tonnes of onion to 6 countries
- KTR accuses Telangana CM of cheating people in phases
- IPL 2024: Samson elects to field as high-flying Rajasthan Royals take on Lucknow Super Giants
- Manikanta Gautam awarded honorary doctorate
- Shehzad Poonawala calls Arvind Kejriwal 'Pablo Escobar' who runs gang from jail
India’s coronary drug-eluting stents mkt to see 4% CAGR by 2033
Already known as the heart disease capital of the world, India is seeing a growing incidence of cardiovascular diseases, especially among young adults, owing to a poor lifestyle.
New Delhi: The coronary drug-eluting stents market in India is set to grow at a compound annual growth rate of 4 per cent between 2023 and 2033, according to a report on Tuesday.
This is driven by the growing incidence of coronary artery diseases, improved access to the latest treatment options, higher diagnosis rates, and technological advancements in the country.
Already known as the heart disease capital of the world, India is seeing a growing incidence of cardiovascular diseases, especially among young adults, owing to a poor lifestyle.
The report by GlobalData, a data and analytics company, showed that India’s coronary drug-eluting stent market accounted for approximately 25 per cent of the Asia-Pacific (APAC) market in 2023.
“Heart diseases in India are growing rapidly, and if this trend persists, the nation could soon record the highest number of deaths from heart diseases. To address this challenge, advances in treatment methods, such as improvements in imaging equipment, stent design, and implantation techniques, are needed,” said Kanchan Chauhan, Medical Devices Analyst at GlobalData, in a statement.
In December 2023, Terumo, a Japanese company, launched Ultimaster Nagomi stent in India, which distinguishes itself by featuring a bioresorbable polymer coating that gradually dissolves after facilitating effective drug delivery, consequently preventing restenosis.
In contrast to traditional drug-eluting stents that use durable polymers, which may cause long-term complications such as chronic inflammation, Terumo’s approach minimises the risk of inflammatory responses, improving overall patient safety.
“India is making rapid progress with regards to cardiovascular treatment. With high class hospitals, the availability of cost-effective treatment options, and skilled cardiologists, the nation is already a favourite destination for medical tourism. With efforts being made to continuously develop and deploy advanced cardiology treatment, India is poised to become a global hub for top-notch cardiology treatment,” Chauhan said.
